ClinicalTrials.gg
RecruitingNCT04684797Updated Jan 5, 2024

Localization of the Reward Positivity to ACC

An interventional study of Virtual T-maze task in Refractory Epilepsy, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Drug Resistant Epilepsy with a site in Belgium — 5 open to participants now, 6 under way, 1 of them phase 3. Drug Resistant Epilepsy · Belgium.

Planned enrollment
8th of 15
40 · median 40
Started
2021
with 1 other
No phase
8 of 17
4 open now
Registered
7th of 17
by date
Lead sponsor
2 of 17
University Hospital, Ghent

Among the 17 studies in Drug Resistant Epilepsy with a site in Belgium, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 8 with no phase, and was the 7th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

5 of the 17 studies in Drug Resistant Epilepsy with a site in Belgium are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Drug Resistant Epilepsy with a site in Belgium, or all of them as a file.
02

Study summary

The exact function of the anterior cingulate cortex (ACC) is one of the largest riddles in cognitive neuroscience and a major challenge in mental health research. ACC dysfunction contributes to a broad spectrum of neurological and psychiatric disorders, such as depression, ADHD, Parkinson's disease, OCD and many others, but nobody knows what it actually does. Recently a new theory has been developed about ACC function; the HRL-ACC (Hierarchical Reinforcement Learning Theory of ACC). This theory proposes that the ACC selects and motivates high-level tasks based on the principles of hierarchical reinforcement learning. The ACC associates values with tasks, selects the correct tasks and applies control over other neural networks (such as the dorsolateral prefrontal cortex and basal ganglia), which execute the tasks. The values of these tasks are attributed based on "reward prediction error signals", which are sent from the midbrain dopamine system to the ACC. These signals can be recorded using scalp-EEG as an "event-related brain potential" (ERP), which is called the "reward positivity". Until this day, the exact origin of the reward positivity is not yet known. Studies have delivered strong indirect evidence that the reward positivity is generated in the ACC. However, there is an important lack of direct evidence to support this hypothesis. The goal of this study is to provide direct evidence that the reward positivity is generated in the ACC by letting a group of patients with refractory epilepsy perform the virtual T-maze task (which is known to elicit reward positivity) and simultaneously recording intracranial video-EEG.

Read the detailed description

This is a monocentric prospective interventional clinical trial that will include patients with refractory epilepsy and for whom a hospitalization at the Centre for Neurophysiological Monitoring (CNM) at the University Hospital Ghent is planned for invasive video-EEG recording. This hospitalization is part of a pre-surgical work-up to determine if the patient is eligible for resective surgery. It is important to note that the decision to plan the patient for invasive video-EEG monitoring is made by neurologists and neurosurgeons specialized in refractory epilepsy and is in no way connected to this study.

Every patient that will be admitted to the CNM for invasive video-EEG monitoring has a consultation with Prof. Dr. Alfred Meurs about one month before hospitalization. During this consultation, Prof. Meurs will ask if the patient is willing to participate in this study. If the patient agrees and has given informed consent, the first session of the study will take place directly after the consultation. However, if the patient is not available at that time, a new appointment will be made for the first session. The first session has to take place before admission to the CNM.

The study consists of two experimental sessions. The first session takes place after giving informed consent and before admission to the hospital for invasive video-EEG monitoring. Therefore, this session is completely study-specific and may require and extra visit to the hospital if the patient is not available right after the consultation with Prof. Meurs.

During this session, the patient will perform the virtual T-maze task for 20 minutes while scalp-EEG will be recorded simultaneously. During this task, patients will see a T-maze on a computer screen and have to choose at every junction whether they go left or right. Depending on the direction they choose, they get rewarded or not. This feedback will elicit the reward positivity.

The rationale for this first session is that it is important to know whether or not the patient produces a normal reward positivity measured by scalp EEG, before the intracranial electrodes are placed.

The second session takes place during the admission at the CNM, after the intracranial electrodes are placed. The invasive video-EEG monitoring is part of a pre-surgical work-up and is planned independently from the study. During this session, the patient will once again have to perform the virtual T-maze task while scalp-EEG and intracranial-EEG will simultaneously be recorded.

After the two sessions, the data will be analysed using ERP analysis and the amplitude of the reward positivity will be calculated for every electrode. It is expected that the amplitude of the reward positivity ERP-component will be largest for patients with electrodes in the frontal lobe, located closely to the ACC. This will deliver direct evidence that the reward positivity is in fact generated in the ACC.

03

Conditions studied

  • Refractory Epilepsy

Keywords

  • Anterior Cingulate Cortex
  • Reward positivity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Patients with epilepsy
  • Planned hospitalization at CNM for invasive video-EEG recording with subdural, epidural and/or depth electrodes
  • Patients have to be able to give themselves
  • Imaging after placement of electrodes (CT and/or MRI) has to be available

Exclusion criteria

Exclusion Criteria:

  • Patients known with dementia or severe cognitive and/or psychiatric disorders that makes it impossible for patients to participate in this study
  • Active alcohol and/or drug abuse
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Each participant will undergo two sessions, consisting of performing the virtual T-maze task, scalp-EEG recording and/or intracranial video-EEG recording.

    Behavioral: Virtual T-maze task

Interventions

  • BehavioralVirtual T-maze task

    Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.

06

What researchers measure

Primary outcomes

  1. Distribution of reward positivity amplitude

    Calculation of amplitude of reward positivity ERP-component recorded by intracranial electrodes and scalp-distribution of amplitude across all subjects

    Time frame: Date of inclusion to date of second session (about one month)

Secondary outcomes

  1. Location in brain most likely to represent source of reward positivity

    Electrode with highest reward positivity amplitude and corresponding location in brain, analysis across all subjects

    Time frame: Date of inclusion to date of second session (about one month)

07

Study locations

1 of 1 sites recruiting
  • Department of Neurology, University Hospital Ghent
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Sep 2024, 42 months after the start.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 42 months is above that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2020
First posted
Dec 28, 2020
StartActual
Mar 4, 2021
Primary completionEst.
Sep 30, 2024
CompletionEst.
Sep 30, 2024
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04684797
Collaborators
University Ghent
Responsible party
Sponsor
First posted
Dec 28, 2020
Start date
Mar 4, 2021
Primary completion
Sep 30, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Jan 5, 2024

Study contacts

Alfred Meurs, MD PhD
Contact
alfred.meurs@ugent.be
+3293326482
Joyce Oerlemans
Contact
joyce.oerlemans@ugent.be
+3293325607
Alfred Meurs, MD PhD
principal investigator · University Hospital Ghent, Department of Neurology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion